Back to News
Market Impact: 0.2
Genmab A Consensus Price Target Raised 32.78% to $56.10
Source: Nasdaq
Analyst InsightsAnalyst Estimates
The average one-year price target for Genmab A (NASDAQGS:GMAB; DB:GE91) was revised to $56.10 per share, up 32.78% from the prior $42.25 estimate dated October 22, 2026. The figures are aggregate analyst targets compiled from multiple institutions; no share-price reaction is reported.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
Ticker Sentiment
GMAB0.35
More News
- Coinbase has been battered over the past month. Morgan Stanley says steer clear
- Reliance’s Record $19 Billion Surge Lifts Nifty, Keeps India Bulls in the Game
- Apple reports after the bell. Options traders expect a big move
- Why is Apple stock falling afterhours today?
- Mizuho lowers Lumentum stock price target on Marvell acquisition
- RA Capital Management sells $9.13M in Lenz Therapeutics shares